CLINICAL_TRIALS
trial_result
· 2022-10-04
Clinical Trial Update: Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia [Phase 2]
Summary
Phase 2 trial investigating oral arsenic trioxide for newly diagnosed acute promyelocytic leukemia is ongoing or results not yet available.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: The University of Hong Kong | Conditions: Acute Promyelocytic Leukemia | Phase 2 | Status: UNKNOWN